2.29
-0.13(-5.37%)
Currency In USD
| Previous Close | 2.42 |
| Open | 2.47 |
| Day High | 2.47 |
| Day Low | 2.29 |
| 52-Week High | 3.44 |
| 52-Week Low | 0.98 |
| Volume | 16,647 |
| Average Volume | 65,308 |
| Market Cap | 92.32M |
| PE | -10.41 |
| EPS | -0.22 |
| Moving Average 50 Days | 2.02 |
| Moving Average 200 Days | 1.86 |
| Change | -0.13 |
If you invested $1000 in BeyondSpring Inc. (BYSI) since IPO date, it would be worth $136.31 as of July 03, 2025 at a share price of $2.29. Whereas If you bought $1000 worth of BeyondSpring Inc. (BYSI) shares 5 years ago, it would be worth $146.98 as of July 03, 2025 at a share price of $2.29.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting
GlobeNewswire Inc.
Jun 03, 2025 11:00 AM GMT
Median PFS at 6.8 months, Disease Control Rate of 77.3%, 15 months OS% at 78% in Metastatic NSCLC Patients after Progression on PD-1/L1 Therapies FLORHAM PARK, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring”
BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting
GlobeNewswire Inc.
May 28, 2025 11:00 AM GMT
FLORHAM PARK, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing cancer therapies, today announces that it will have a p
BeyondSpring Files 2024 Annual Report on Form 10-K
GlobeNewswire Inc.
Mar 27, 2025 11:05 AM GMT
FLORHAM PARK, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company developing innovative cancer therapies, today announced that it has filed i